Myriad Genetics

About Myriad Genetics

Myriad Genetics is a company focused on advancing health through genetic testing. They aim to provide personalized healthcare insights by unlocking genetic and genomic information to detect health risks, tailor treatments, and prevent diseases with precision. Their mission includes improving health equity and accessibility to genetic testing for all.

Products & Services

MyRisk:Identifies risk of developing 11 hereditary cancers, leveraging family history and genetic data.

Precise Tumor:Identifies actionable genomic variants and biomarkers associated with FDA-approved therapies.

MyChoice CDx:Identifies HRD status to inform cancer treatment strategies.

Prolaris:Identifies prostate cancer aggressiveness to guide treatment options.

Foresight:Identifies at-risk couples for pregnancies affected by inherited conditions.

Prequel:Identifies risk of chromosomal conditions for expectant parents.

SneakPeek:Identifies fetal sex as early as six weeks into pregnancy.

GeneSight:Identifies how genes affect outcomes with certain mental health medications.

BRACAnalysis CDx:A germline test for cancer risk assessment.

Specialties

Genetic Testing Genomic Profiling Hereditary Cancer Risk Assessment Reproductive Health Oncology Urology Mental Health Pharmacogenomics Prenatal Screening

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 200000000 MR: - FA: up to $200 million FAN: 200000000	D: 2025-07-31 FD: 2025-07-31	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: $100.0 million FAN: 100000000	D: 2023-11-08 FD: 2023-11-08	3 investors
3	RT: Public Offering T: - FT: Public Offering	A: 110000000 MR: - FA: approximately $110 million FAN: 110000000	D: 2023-11-08 FD: 2023-11-08	3 investors
4	RT: Asset Based Credit Facility T: - FT: Asset Based Credit Facility	A: 90000000 MR: - FA: $90 million FAN: 90000000	D: 2023-07-06 FD: 2023-07-06	3 investors

Debt Latest

2025-07-31

$200.0M

1 investor (Pro only)

Public Offering 2023-11-08

$100.0M

Public Offering 2023-11-08

$110.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sam Raha

President and CEO

M

Maggie Ancona

EVP of Strategy & Transformation

D

Dr. Patrick Burke

EVP of Innovation and Strategic Partnerships

B

Brian Donnelly

Chief Commercial Officer

J

Jennifer Fox

Chief Legal Officer

D

Dr. Kevin R. Haas

Chief Technology Officer

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

Myriad Genetics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised